SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan Ministry of Health, Labour and Welfare.
The company reports that, in collaboration with its partner, Biotechno Pharma, it has fulfilled an order of TEPOXX to contribute to Japan’s national stockpile.
In a statement, Diem Nguyen, CEO of SIGA, said, “The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical antiviral treatment worldwide to support an effective response to an orthopoxvirus outbreak.”
“This approval highlights the importance of stockpiling effective antiviral therapies as a cornerstone of innovative solutions to safeguard public health against serious and potentially devastating infectious diseases, such as smallpox,” Mr. Nguyen added.
